Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

127.50 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 100
Open 127.50
Bid (Size) 127.50 (1)
Ask (Size) 130.02 (1)
Prev. Close 127.50
Today's Range 127.50 - 127.50
52wk Range 110.03 - 236.48
Shares Outstanding 145,800,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?
BofA cuts Bristol Myers' 2025 EPS and sales estimates slightly and flags medium-term pressure from generics, while maintaining a Neutral rating. 
Via Benzinga
3 Low-Volatility Stocks in Hot Water
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory

Performance

YTD
-15.0%
-15.0%
1 Month
-2.7%
-2.7%
3 Month
+9.0%
+9.0%
6 Month
-10.9%
-10.9%
1 Year
-42.5%
-42.5%

More News

Read More
Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
From Biogen Inc.
Via GlobeNewswire
What's Driving the Market Sentiment Around Biogen?
Via Benzinga
What Does the Market Think About Biogen?
Via Benzinga
Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
From Stoke Therapeutics, Inc.
Via Business Wire
Biogen Shares Slip After $46M Research Charge Hits Quarterly Profit
Via Stocktwits
1 Value Stock with Exciting Potential and 2 to Approach with Caution
Via StockStory
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
From Biogen Inc.
Via GlobeNewswire
New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA
From Biogen Inc.
Via GlobeNewswire
Biogen-Ionis Partnered Drug Shows Benefit In Children With Spinal Muscular Atrophy Previously Treated With Novartis' Zolgensma
Via Benzinga
Nvidia To Rally Around 69%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
From Biogen Inc.
Via GlobeNewswire
Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug?
Via Investor's Business Daily
Sage Therapeutics Stock: JPMorgan Sees 8% Downside After Supernus Buyout Terms
Via Stocktwits
Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
From Biogen Inc.
Via GlobeNewswire
Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics
Via Stocktwits
Topics Government
Supernus Pharma Acquires Maker Of Postpartum Depression Drug Zurzuvae In $795 Million Deal
Via Benzinga
Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million
Via Investor's Business Daily
Topics ETFs
1 Profitable Stock with Exciting Potential and 2 to Avoid
Via StockStory
Biogen, UCB Take A Leap In Lupus With Promising Phase 3 Results
Via Benzinga
Demystifying Biogen: Insights From 11 Analyst Reviews
Via Benzinga
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity
From Biogen Inc.
Via GlobeNewswire
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Q1 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence

Frequently Asked Questions

Is Biogen Idec publicly traded?
Yes, Biogen Idec is publicly traded.
What exchange does Biogen Idec trade on?
Biogen Idec trades on the Nasdaq Stock Market
What is the ticker symbol for Biogen Idec?
The ticker symbol for Biogen Idec is BIIB on the Nasdaq Stock Market
What is the current price of Biogen Idec?
The current price of Biogen Idec is 127.50
When was Biogen Idec last traded?
The last trade of Biogen Idec was at 07/15/25 04:00 PM ET
What is the market capitalization of Biogen Idec?
The market capitalization of Biogen Idec is 18.59B
How many shares of Biogen Idec are outstanding?
Biogen Idec has 19B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.